Haini Pharmaceutical
Zhejiang, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese pharma company developing innovative small molecule therapies for cardiovascular and metabolic disorders.
CardiovascularMetabolic
Technology Platform
Modern small molecule drug discovery platform utilizing structure-based design and medicinal chemistry for cardiometabolic targets.
Opportunities
Large and growing patient population for cardiometabolic diseases in China creates a major market for effective novel therapies.
Risk Factors
High clinical development risk and the challenge of differentiating from established, often genericized, standard-of-care treatments.
Competitive Landscape
Competes directly with massive global pharma companies with entrenched cardiometabolic franchises and extensive commercial capabilities.